{"id":163051,"date":"2026-07-22T10:40:17","date_gmt":"2026-07-22T05:10:17","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=163051"},"modified":"2026-07-22T10:40:19","modified_gmt":"2026-07-22T05:10:19","slug":"anthem-biosciences-q1-results-fy27-pat-119-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/","title":{"rendered":"Anthem Biosciences Q1 Results FY27: Net Profit Falls 11.7% to Rs 119 Crore as Revenue Declines 22.6%"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Anthem Biosciences Q1 FY27: consolidated PAT Rs 119 Cr, down 11.7% YoY. Revenue Rs 418 Cr, down 22.6%. Gross profit down 26.9% at Rs 120 Cr. Shares trading down 2.53% as of 22 July 2026.<\/em><\/p>\n<p>Anthem Biosciences Q1 results FY27 were announced on Tuesday, 21 July 2026, with the company reporting the numbers summarised below on a consolidated basis for the quarter ended 30 June 2026.<\/p>\n<p>Shares of <a href=\"https:\/\/univest.in\/stocks\/anthem\/anthem-biosciences-ltd-share-price-today\">Anthem Biosciences<\/a> were trading down 2.93 at Rs 768.35 on the NSE as of Wednesday, 22 July 2026. The contract research, development and manufacturing (CRDMO) company, among the more recent additions to the exchanges, reported a decline across every metric.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=anthem-biosciences-q1-fy27-pat\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#Anthem_Biosciences_Q1_Results_FY27_Key_Takeaways\" title=\"Anthem Biosciences Q1 Results FY27 Key Takeaways\">Anthem Biosciences Q1 Results FY27 Key Takeaways<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#Anthem_Biosciences_Q1_Results_FY27_Financial_Highlights\" title=\"Anthem Biosciences Q1 Results FY27 Financial Highlights\">Anthem Biosciences Q1 Results FY27 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#Anthem_Biosciences_Q1_Results_FY27_Performance_Analysis\" title=\"Anthem Biosciences Q1 Results FY27 Performance Analysis\">Anthem Biosciences Q1 Results FY27 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#Anthem_Biosciences_Q1_Results_FY27_Key_Business_Factors\" title=\"Anthem Biosciences Q1 Results FY27: Key Business Factors\">Anthem Biosciences Q1 Results FY27: Key Business Factors<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#1_Revenue_Decline_Steeper_Than_Profit_Decline\" title=\"1. Revenue Decline Steeper Than Profit Decline\">1. Revenue Decline Steeper Than Profit Decline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#2_Possible_Project_Timing_Effects\" title=\"2. Possible Project Timing Effects\">2. Possible Project Timing Effects<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#3_Margin_Compression_at_the_Gross_Level\" title=\"3. Margin Compression at the Gross Level\">3. Margin Compression at the Gross Level<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#Dividend_Details\" title=\"Dividend Details\">Dividend Details<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#Anthem_Biosciences_Q1_Results_FY27_Outlook_for_the_Full_Year\" title=\"Anthem Biosciences Q1 Results FY27 Outlook for the Full Year\">Anthem Biosciences Q1 Results FY27 Outlook for the Full Year<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#Anthem_Biosciences_Stock_Performance_After_the_Q1_Results\" title=\"Anthem Biosciences Stock Performance After the Q1 Results\">Anthem Biosciences Stock Performance After the Q1 Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#Key_Risks\" title=\"Key Risks\">Key Risks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#1_Contract_and_Revenue_Lumpiness\" title=\"1. Contract and Revenue Lumpiness\">1. Contract and Revenue Lumpiness<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#2_Client_Concentration_Risk\" title=\"2. Client Concentration Risk\">2. Client Concentration Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#3_Recently_Listed_Stock_Volatility\" title=\"3. Recently Listed Stock Volatility\">3. Recently Listed Stock Volatility<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#Frequently_Asked_Questions_on_Anthem_Biosciences_Q1_Results_FY27\" title=\"Frequently Asked Questions on Anthem Biosciences Q1 Results FY27\">Frequently Asked Questions on Anthem Biosciences Q1 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#When_were_the_Anthem_Biosciences_Q1_results_FY27_announced\" title=\"When were the Anthem Biosciences Q1 results FY27 announced?\">When were the Anthem Biosciences Q1 results FY27 announced?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#What_is_the_PAT_in_the_Anthem_Biosciences_Q1_results_FY27\" title=\"What is the PAT in the Anthem Biosciences Q1 results FY27?\">What is the PAT in the Anthem Biosciences Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#What_was_the_revenue_in_the_Anthem_Biosciences_Q1_results_FY27\" title=\"What was the revenue in the Anthem Biosciences Q1 results FY27?\">What was the revenue in the Anthem Biosciences Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#Why_did_Anthem_Biosciences_revenue_fall_in_Q1_FY27\" title=\"Why did Anthem Biosciences revenue fall in Q1 FY27?\">Why did Anthem Biosciences revenue fall in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#What_does_Anthem_Biosciences_do\" title=\"What does Anthem Biosciences do?\">What does Anthem Biosciences do?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#How_is_the_stock_trading_after_the_Anthem_Biosciences_Q1_results_FY27\" title=\"How is the stock trading after the Anthem Biosciences Q1 results FY27?\">How is the stock trading after the Anthem Biosciences Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#Is_the_stock_a_good_buy_after_the_Anthem_Biosciences_Q1_results_FY27\" title=\"Is the stock a good buy after the Anthem Biosciences Q1 results FY27?\">Is the stock a good buy after the Anthem Biosciences Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-q1-results-fy27-pat-119-crore\/#Where_can_I_verify_the_Anthem_Biosciences_Q1_results_FY27\" title=\"Where can I verify the Anthem Biosciences Q1 results FY27?\">Where can I verify the Anthem Biosciences Q1 results FY27?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Anthem_Biosciences_Q1_Results_FY27_Key_Takeaways\"><\/span><strong>Anthem Biosciences Q1 Results FY27 Key Takeaways<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Here are the most important numbers from the Anthem Biosciences Q1 results FY27 at a glance.<\/p>\n<ul>\n<li>Revenue: Rs 418 Cr in Q1 FY27 versus Rs 540 Cr in Q1 FY26, down 22.6% year on year.<\/li>\n<li>Gross Profit: Rs 120 Cr in Q1 FY27 versus Rs 165 Cr in Q1 FY26, down 26.9% year on year.<\/li>\n<li>Net Profit (PAT): Rs 119 Cr in Q1 FY27 versus Rs 135 Cr in Q1 FY26, down 11.7% year on year.<\/li>\n<li>Anthem Biosciences shares were trading down 2.93 at Rs 768.35 as of Wednesday, 22 July 2026.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Anthem_Biosciences_Q1_Results_FY27_Financial_Highlights\"><\/span><strong>Anthem Biosciences Q1 Results FY27 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below summarises the consolidated numbers reported in the Anthem Biosciences Q1 results FY27 against the year ago quarter.<\/p>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Q1 FY27<\/th>\n<th>Q1 FY26<\/th>\n<th>YoY Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Revenue<\/td>\n<td>Rs 418 Cr<\/td>\n<td>Rs 540 Cr<\/td>\n<td>-22.6%<\/td>\n<\/tr>\n<tr>\n<td>Gross Profit<\/td>\n<td>Rs 120 Cr<\/td>\n<td>Rs 165 Cr<\/td>\n<td>-26.9%<\/td>\n<\/tr>\n<tr>\n<td>Net Profit (PAT)<\/td>\n<td>Rs 119 Cr<\/td>\n<td>Rs 135 Cr<\/td>\n<td>-11.7%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All figures are on a consolidated basis as reported for the quarter ended 30 June 2026.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Anthem_Biosciences_Q1_Results_FY27_Performance_Analysis\"><\/span><strong>Anthem Biosciences Q1 Results FY27 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/sebi-registered-investment-advisor-india\"><strong>Get Personalised Guidance from a SEBI-Registered Investment Advisor<\/strong><\/a><\/p>\n<p>The Anthem Biosciences Q1 results FY27 show a broad based decline, with revenue falling 22.6%, gross profit falling further at 26.9%, and net profit falling a comparatively smaller 11.7%. The fact that PAT fell less than revenue and gross profit suggests some cost flexibility or a favourable item below the operating line cushioned the bottom line.<\/p>\n<p>For a CRDMO business serving pharmaceutical and biotech clients, revenue can be lumpy quarter to quarter depending on the timing of large development and manufacturing contracts. A 22.6% revenue decline in the Anthem Biosciences Q1 results FY27 may reflect the phasing of specific projects rather than a broad demand slowdown, though this needs confirmation from management commentary.<\/p>\n<p>The relatively contained stock reaction of a 2.93% decline, smaller than the scale of the revenue and gross profit falls, suggests the market may already be pricing in some quarter to quarter lumpiness typical of contract research and manufacturing businesses.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Anthem_Biosciences_Q1_Results_FY27_Key_Business_Factors\"><\/span><strong>Anthem Biosciences Q1 Results FY27: Key Business Factors<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_Revenue_Decline_Steeper_Than_Profit_Decline\"><\/span><strong>1. Revenue Decline Steeper Than Profit Decline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>PAT falling 11.7% against a 22.6% revenue decline in the Anthem Biosciences Q1 results FY27 suggests the company retained some cost flexibility or had a favourable item below the operating line.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Possible_Project_Timing_Effects\"><\/span><strong>2. Possible Project Timing Effects<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>As a CRDMO business, revenue often depends on the phasing of large pharmaceutical development and manufacturing contracts, which can create lumpy quarter to quarter comparisons.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Margin_Compression_at_the_Gross_Level\"><\/span><strong>3. Margin Compression at the Gross Level<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Gross profit falling 26.9%, faster than revenue, in the Anthem Biosciences Q1 results FY27 indicates some margin pressure within the core operations that investors should track into the next quarter.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dividend_Details\"><\/span><strong>Dividend Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Any dividend announcement accompanying the June 2026 quarter results will be reflected in the company&#8217;s official NSE and BSE filings. Investors should rely on those filings for dividend confirmation rather than secondary sources.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Anthem_Biosciences_Q1_Results_FY27_Outlook_for_the_Full_Year\"><\/span><strong>Anthem Biosciences Q1 Results FY27 Outlook for the Full Year<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>After the Anthem Biosciences Q1 results FY27, the key question is whether the revenue decline reflects contract timing that will reverse in coming quarters or a more sustained demand softness. Management commentary on the CRDMO order pipeline and new contract wins will be important signals for FY27.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Anthem_Biosciences_Stock_Performance_After_the_Q1_Results\"><\/span><strong>Anthem Biosciences Stock Performance After the Q1 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Anthem Biosciences live share price and upcoming quarterly results.<\/em><\/p>\n<p>Anthem Biosciences shares were trading down 2.93 at Rs 768.35 on the NSE as of Wednesday, 22 July 2026, a day after the Anthem Biosciences Q1 results FY27 were announced.<\/p>\n<p>Investors can compare the trend of the counter with the <a href=\"https:\/\/univest.in\/indices\/nifty-500\/nifty-500-share-price-today\">Nifty 500<\/a> index to judge how the stock is placed relative to the broader market after the Anthem Biosciences Q1 results FY27.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks\"><\/span><strong>Key Risks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Investors going through the fine print of the Anthem Biosciences Q1 results FY27 should also weigh the following risks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"1_Contract_and_Revenue_Lumpiness\"><\/span><strong>1. Contract and Revenue Lumpiness<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>CRDMO revenue can swing significantly quarter to quarter based on project timing, making the Anthem Biosciences Q1 results FY27 potentially not fully representative of the underlying demand trend.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Client_Concentration_Risk\"><\/span><strong>2. Client Concentration Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Contract research and manufacturing businesses often have revenue concentrated among a smaller number of large pharmaceutical and biotech clients, a structural risk.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Recently_Listed_Stock_Volatility\"><\/span><strong>3. Recently Listed Stock Volatility<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>As a relatively recent listing, the stock may see sharper price swings on quarterly results until a longer track record of consistent performance is established.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Anthem Biosciences Q1 results FY27 show net profit down 11.7% at Rs 119 crore on a steeper 22.6% revenue decline, a mixed print for the CRDMO company. Investors should track order pipeline commentary into the September quarter and consult a SEBI-registered advisor before acting on the numbers.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Anthem_Biosciences_Q1_Results_FY27\"><\/span><strong>Frequently Asked Questions on Anthem Biosciences Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"When_were_the_Anthem_Biosciences_Q1_results_FY27_announced\"><\/span><strong>When were the Anthem Biosciences Q1 results FY27 announced?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Anthem Biosciences Q1 results FY27 were announced on Tuesday, 21 July 2026, for the quarter ended 30 June 2026, on a consolidated basis.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_PAT_in_the_Anthem_Biosciences_Q1_results_FY27\"><\/span><strong>What is the PAT in the Anthem Biosciences Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The consolidated PAT in the Anthem Biosciences Q1 results FY27 stood at Rs 119 crore, down 11.7% from Rs 135 crore in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_revenue_in_the_Anthem_Biosciences_Q1_results_FY27\"><\/span><strong>What was the revenue in the Anthem Biosciences Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue in the Anthem Biosciences Q1 results FY27 stood at Rs 418 crore, down 22.6% from Rs 540 crore in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_did_Anthem_Biosciences_revenue_fall_in_Q1_FY27\"><\/span><strong>Why did Anthem Biosciences revenue fall in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Anthem Biosciences Q1 results FY27 show a 22.6% revenue decline, which may reflect the timing of large contract research and manufacturing projects typical of the CRDMO business model rather than a broad demand slowdown, though this needs confirmation from management commentary.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_does_Anthem_Biosciences_do\"><\/span><strong>What does Anthem Biosciences do?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The company is a contract research, development and manufacturing organisation (CRDMO) serving pharmaceutical and biotechnology clients.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_is_the_stock_trading_after_the_Anthem_Biosciences_Q1_results_FY27\"><\/span><strong>How is the stock trading after the Anthem Biosciences Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Anthem Biosciences shares were trading down 2.93% at Rs 768.35 on the NSE as of Wednesday, 22 July 2026, a day after the Anthem Biosciences Q1 results FY27 were announced.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_the_stock_a_good_buy_after_the_Anthem_Biosciences_Q1_results_FY27\"><\/span><strong>Is the stock a good buy after the Anthem Biosciences Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Anthem Biosciences Q1 results FY27 show a broad based decline that warrants tracking the order pipeline for signs of a rebound. This article is for educational purposes only. Consult a SEBI-registered advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_verify_the_Anthem_Biosciences_Q1_results_FY27\"><\/span><strong>Where can I verify the Anthem Biosciences Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The official filings for the June 2026 quarter are available on the NSE and BSE websites, and the stock can be tracked on the Univest app.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Anthem Biosciences Q1 results FY27: net profit falls 11.7% to Rs 119 crore as revenue declines 22.6%, a mixed quarter for the CRDMO company. Shares trading down 2.93% as of 22 July 2026.<\/p>\n","protected":false},"author":28,"featured_media":163089,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-163051","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1784697021:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["77"],"rank_math_title":["Anthem Biosciences Q1 Results FY27: PAT Falls 11.7%"],"rank_math_description":["Anthem Biosciences Q1 results FY27: PAT falls 11.7% to Rs 119 Cr as revenue declines 22.6% for the CRDMO company. Full highlights, analysis and FY27 outlook here."],"rank_math_focus_keyword":["Anthem Biosciences Q1 Results"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_thumbnail_id":["163089"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["29032"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/07\/Anthem-Biosciences-Q1-Results.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/163051","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=163051"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/163051\/revisions"}],"predecessor-version":[{"id":163090,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/163051\/revisions\/163090"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/163089"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=163051"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=163051"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=163051"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}